Inhaled Anti-Infective Agents: Types, Mechanisms, and Uses

Inhaled anti-infective agents are medications delivered directly into the respiratory tract to prevent, treat, or manage selected pulmonary infections.

This route allows the drug to reach the airways and lung tissue more directly than many systemic therapies, which may improve local drug exposure while limiting some systemic effects. These medications are not used for every respiratory infection.

Instead, they are reserved for specific organisms, patient groups, and clinical situations, such as cystic fibrosis with chronic Pseudomonas infection, severe RSV disease, influenza, or prophylaxis against Pneumocystis pneumonia.

What Are Inhaled Anti-Infective Agents?

Inhaled anti-infective agents are antimicrobial medications administered by aerosol, nebulizer, or dry powder inhaler to target infections in the respiratory tract. The term “anti-infective” is broad because it includes drugs that act against bacteria, viruses, fungi, protozoa, and other microorganisms. In respiratory care, these agents are important because many infections involve the airways, lung parenchyma, or lower respiratory tract secretions.

The terms antimicrobial, antibiotic, antiviral, and anti-infective are related but not identical. An antimicrobial is a substance that acts against microorganisms. An antibiotic generally refers to a drug used against bacteria, although the term is sometimes used loosely. An antiviral acts against viruses. An anti-infective is the broadest term and includes medications used to prevent or treat infections caused by a variety of organisms.

The main inhaled anti-infective agents include:

• Pentamidine
• Ribavirin
• Tobramycin
• Aztreonam
• Colistimethate sodium, also called colistin
• Zanamivir

Each medication has a distinct purpose. Tobramycin, aztreonam, and colistin are mainly associated with bacterial infection, especially Pseudomonas aeruginosa in cystic fibrosis. Ribavirin and zanamivir are antivirals. Pentamidine is an antiprotozoal medication used primarily for prophylaxis against Pneumocystis pneumonia in selected high-risk patients.

Why Use the Inhaled Route?

The inhaled route can place medication close to the site of respiratory infection. This is especially useful when the infection involves the airways and secretions, as in cystic fibrosis. In some cases, inhalation allows high local airway concentrations that may be difficult to achieve safely through systemic administration.

This does not mean inhaled therapy is always safer or better. Aerosolized drugs can irritate the airway, cause bronchospasm, expose caregivers to fugitive aerosol, contaminate the environment, and require specialized equipment. Some inhaled medications also have systemic risks, especially when the drug class is known for toxicity.

The inhaled route may be useful when the goal is to:

• Deliver high drug concentrations to the respiratory tract
• Treat chronic airway infection
• Reduce systemic exposure when possible
• Target organisms in airway secretions
• Support prophylaxis in selected high-risk patients
• Provide antiviral therapy for specific respiratory viral infections

Note: Inhaled anti-infectives require careful patient selection. They are not routine medications for uncomplicated pneumonia, bronchitis, or viral respiratory infections. Their use should be linked to the organism, clinical indication, patient condition, and delivery device.

Common Pathogens in Respiratory Infections

Respiratory infections can be caused by bacteria, viruses, fungi, protozoa, and other organisms. The suspected or confirmed pathogen strongly influences drug selection.

Common bacterial organisms include:

• Streptococcus pneumoniae
• Staphylococcus aureus
• Haemophilus influenzae
• Klebsiella pneumoniae
• Pseudomonas aeruginosa
• Serratia species

Common viral organisms include:

• Rhinovirus
• Adenovirus
• Respiratory syncytial virus
• Influenza virus
• Varicella virus
• Herpes simplex virus
• Cytomegalovirus

Fungal and opportunistic organisms may include:

• Candida albicans
• Aspergillus species
• Pneumocystis jirovecii
• Histoplasma capsulatum
• Coccidioides immitis

Some organisms are especially important in debilitated or immunocompromised patients. These include Pneumocystis, Staphylococcus aureus, Pseudomonas aeruginosa, Serratia, Mycobacterium tuberculosis, and several fungal pathogens.

This matters because inhaled anti-infective therapy is often used in highly specific settings, not as broad treatment for any respiratory infection.

Key Patient Populations

Inhaled anti-infective agents are used most often in patient groups where infection is severe, recurrent, chronic, or linked to a specific organism.

Cystic Fibrosis

Cystic fibrosis is one of the most important conditions associated with inhaled antibiotics. It is an inherited disorder that causes abnormal exocrine gland function. In the lungs, this leads to thick secretions, impaired mucociliary clearance, chronic airway obstruction, repeated infections, and progressive decline in pulmonary function.

Patients with cystic fibrosis may develop chronic airway infection with Pseudomonas aeruginosa. This organism is strongly associated with worsening lung function, increased exacerbations, and the need for intensive antibiotic therapy. Inhaled antibiotics such as tobramycin, aztreonam, and colistin may be used to help control Pseudomonas infection and reduce clinical deterioration.

Immunocompromised Patients

Patients with impaired immune function may be at risk for opportunistic infections. Pneumocystis jirovecii pneumonia, also called PJP, is one example. This infection is most often associated with severely immunocompromised patients, including individuals with HIV or AIDS and very low CD4+ lymphocyte counts.

Pentamidine may be used by aerosol for prophylaxis when preferred therapy is not tolerated or not appropriate. It is important to remember that aerosolized pentamidine is mainly preventive and is not considered the main treatment for active Pneumocystis pneumonia.

Infants and High-Risk Children With Severe RSV

Respiratory syncytial virus, or RSV, can cause bronchiolitis and pneumonia, especially in infants and young children. Most RSV infections are managed with supportive care. Inhaled ribavirin is not routine therapy for most patients with RSV. It may be considered in severe or life-threatening lower respiratory tract infection, especially in high-risk patients such as those with prematurity, chronic lung disease, congenital heart disease, or immunocompromise.

Patients With Influenza

Zanamivir is an inhaled antiviral used for influenza. It is delivered by dry powder inhaler and may be used for treatment of uncomplicated acute influenza when symptoms have been present for a short period, commonly no more than two days. It may also be used for prophylaxis in selected situations. Since zanamivir is a dry powder medication, it requires adequate inspiratory effort and proper inhaler technique.

Tobramycin

Tobramycin is an aminoglycoside antibiotic commonly used by inhalation in patients with cystic fibrosis who have Pseudomonas aeruginosa infection. It is one of the most important inhaled anti-infective agents for respiratory therapy students and clinicians to understand.

In cystic fibrosis, thick secretions and impaired clearance allow bacteria to persist in the airways. Pseudomonas aeruginosa may become chronic and difficult to eradicate. Inhaled tobramycin provides high local antibiotic exposure in the airways while limiting systemic levels compared with intravenous therapy.

Indications

Inhaled tobramycin is mainly used for management of Pseudomonas aeruginosa infection in patients with cystic fibrosis. It is intended to control chronic infection, improve clinical outcomes, and reduce disease burden. It is not used as a general antibiotic for every patient with pneumonia.

Tobramycin is commonly recognized by the brand name TOBI. It may be delivered through a small-volume nebulizer, such as the PARI LC Plus, or through a dry powder format, such as the TOBI Podhaler, depending on the formulation.

Administration

A common treatment pattern involves alternating cycles, such as 28 days on therapy followed by 28 days off therapy. This intermittent schedule may help control infection while reducing the risk of resistance and allowing susceptible organisms to repopulate during drug-free intervals.

Tobramycin should be administered by itself. It should not be mixed with other medications in the nebulizer. This is especially important because tobramycin is incompatible with beta-lactam antibiotics, such as penicillins and cephalosporins. In general, mixing inhaled antibiotics with other aerosol medications is discouraged unless specifically directed by the manufacturer or prescriber.

Adverse Effects and Precautions

Although inhaled tobramycin is delivered locally, it still requires careful monitoring. Aminoglycosides are associated with renal, auditory, vestibular, and neuromuscular toxicity. These risks are lower with inhaled therapy than with systemic therapy, but they are not irrelevant.

Important concerns include:

• Voice alteration
• Tinnitus
• Hearing changes
• Renal problems
• Vestibular symptoms
• Bronchospasm
• Cough
• Airway irritation
• Reduced ventilatory flow rates

Tobramycin should be used cautiously in patients with preexisting kidney disease, hearing impairment, vestibular problems, or neuromuscular disorders. Caution is also needed if the patient is receiving other aminoglycosides, loop diuretics, or ototoxic medications. Because aminoglycosides may cause fetal harm, pregnant individuals or those trying to become pregnant should avoid exposure to ambient aerosol.

Monitoring Effectiveness

Monitoring should include both short-term tolerance and long-term clinical response. Clinicians may assess breath sounds, work of breathing, cough, sputum production, oxygenation, and symptoms before and after therapy. Peak flow or spirometry may be used to identify bronchospasm or flow limitation.

Long-term evaluation may include:

• FEV₁ trends
• Frequency of hospitalization
• Need for intravenous antipseudomonal therapy
• Weight gain or nutritional status
• Frequency of pulmonary exacerbations
• Hearing status
• Renal function
• Patient adherence
• Side effects such as tinnitus or voice changes

Note: Patients should be instructed to rinse and expectorate after treatment to reduce local irritation and residue.

Aztreonam

Aztreonam is a monobactam antibiotic used by inhalation in selected patients with cystic fibrosis and Pseudomonas aeruginosa infection. The inhaled form is commonly known by the brand name Cayston.

Aztreonam has activity against gram-negative aerobic bacteria. Its mechanism involves binding to penicillin-binding proteins, inhibiting bacterial cell wall synthesis, and causing bacterial cell death. In cystic fibrosis, it is used to improve pulmonary symptoms associated with Pseudomonas infection.

Indications

Inhaled aztreonam is used for cystic fibrosis patients with Pseudomonas aeruginosa infection. It is not intended for cystic fibrosis patients who are not infected with Pseudomonas. Unnecessary antibiotic exposure can contribute to drug-resistant bacteria and should be avoided.

It is also not indicated for very young patients or for patients with Burkholderia cepacia infection. Proper patient selection is essential.

Device Requirements

Aztreonam is administered using a specific nebulizer system. Cayston is associated with electronic vibrating mesh nebulizer delivery, such as the Altera system. This matters because inhaled anti-infective agents are not interchangeable across all aerosol devices. The prescribed formulation often determines the correct delivery system.

A respiratory therapist should not substitute a standard small-volume nebulizer simply because it is available or convenient. Device selection must match the medication’s approved delivery method.

Administration Sequence

Patients with cystic fibrosis often receive several inhaled therapies. The sequence can affect tolerance and deposition. In general, the antibiotic is given after therapies that open the airways, mobilize secretions, and clear mucus.

A useful sequence is:

• Bronchodilator
• Mucolytic or secretion-mobilizing therapy
• Airway clearance therapy
• Inhaled corticosteroid, if ordered
• Aerosolized antibiotic

Note: A practical phrase is: open, thin, clear, calm, kill. Open the airways, thin or mobilize secretions, clear the airway, calm inflammation when ordered, and deliver the antibiotic last.

Adverse Effects and Precautions

The major adverse effects of inhaled aztreonam include bronchospasm and decreased FEV₁. For this reason, baseline pulmonary function should be assessed before therapy. A fast-acting beta-adrenergic bronchodilator is often given before inhaled aztreonam to reduce the risk of bronchospasm.

Potential concerns include:

• Bronchospasm
• Cough
• Wheezing
• Chest tightness
• Decreased FEV₁
• Allergic reaction
• Airway irritation

Note: Severe allergic reactions have been reported with injectable aztreonam, so careful observation is important when starting inhaled aztreonam. If hypersensitivity signs occur, treatment should be stopped and the health care team notified.

Colistimethate Sodium

Colistimethate sodium, commonly called colistin or polymyxin E, is an antibiotic used against sensitive gram-negative bacilli, including Pseudomonas aeruginosa. It has relevance in cystic fibrosis because chronic Pseudomonas infection is a major problem in this patient population.

Colistin may be delivered through inhalation in some settings. Inhaled formulations are available in some places, and nebulization of the parenteral formulation has also been used in patients with cystic fibrosis. Because formulation and delivery practices may vary, clinicians must follow institutional policy, manufacturer guidance, and prescriber instructions.

Indications

Colistin may be considered for chronic or refractory gram-negative respiratory tract infections, especially those involving Pseudomonas. It is not an automatic choice for all gram-negative infections. Therapy should be guided by culture results, drug sensitivity, clinical status, and the patient’s underlying disease.

Adverse Effects and Monitoring

Systemic colistimethate has been associated with nephrotoxicity and neurotoxicity. Even when delivered by inhalation, monitoring remains important.

Potential adverse effects include:

• Bronchospasm
• Cough
• Airway irritation
• Kidney toxicity
• Neurologic symptoms
• Chest tightness
• Wheezing

Note: As with other inhaled antibiotics, therapy should be targeted to the organism and reassessed if the patient does not improve or develops significant adverse effects.

Pentamidine

Pentamidine isethionate is an antiprotozoal medication associated with Pneumocystis jirovecii pneumonia, formerly called Pneumocystis carinii pneumonia. This infection is often abbreviated as PJP or PCP. It is an opportunistic infection most often seen in patients with impaired immune function.

Oral trimethoprim-sulfamethoxazole is generally preferred when tolerated. Aerosolized pentamidine may be used as an alternative for primary or secondary prophylaxis when the preferred medication is not appropriate. A critical point is that inhaled pentamidine is not the main treatment for active Pneumocystis pneumonia. Its main role is prevention in selected high-risk patients.

Indications

Pentamidine may be used for prophylaxis against Pneumocystis pneumonia in high-risk patients, including some HIV-infected patients with very low CD4+ lymphocyte counts or a history of prior disease. The adult aerosol dose is commonly described as 300 mg of powder mixed with sterile water and delivered by small-volume nebulizer once every 4 weeks, depending on the prescribed regimen.

Adverse Effects

Pentamidine can cause local airway effects and systemic side effects. Respiratory effects are especially important because bronchospasm may occur during aerosol administration.

Possible respiratory effects include:

• Cough
• Bronchial irritation
• Wheezing
• Bronchospasm
• Shortness of breath
• Chest pain
• Pneumothorax

Other possible effects include:

• Bad or metallic taste
• Pharyngitis
• Conjunctivitis
• Rash
• Fatigue
• Nausea
• Dizziness
• Chills
• Night sweats
• Decreased appetite
• Renal insufficiency
• Hypoglycemia
• Neutropenia
• Pancreatitis

Note: Prophylactic inhaled pentamidine may not fully prevent extrapulmonary Pneumocystis infection. This means the infection may still occur outside the lungs even if pulmonary prophylaxis is being used.

Bronchospasm Prevention

Patients receiving aerosolized pentamidine should be monitored closely, especially if they have reactive airways. Pretreatment with a short-acting beta agonist or an anticholinergic bronchodilator may be used in some patients to reduce bronchospasm risk.

The therapist should assess breath sounds, cough, respiratory rate, work of breathing, oxygen saturation, and patient comfort before, during, and after therapy. If the patient develops significant wheezing, chest tightness, or shortness of breath, treatment may need to be interrupted and the prescriber notified.

Environmental Safety

Pentamidine aerosol can escape into the room during nebulizer treatment. This creates a risk of exposure for health care workers and bystanders. Nebulized patient secretions may also enter the environment, creating an infection-control concern.

A filtered nebulizer system is recommended. One-way valves and downstream particle filters can help trap exhaled aerosol droplets and reduce environmental contamination. Negative-pressure rooms, booths, scavenging systems, and appropriate personal protective equipment may be used depending on the facility and patient situation.

Ribavirin

Ribavirin is an inhaled antiviral agent used primarily for severe respiratory syncytial virus infection. RSV can cause lower respiratory tract disease, especially in infants, young children, and high-risk patients.

Ribavirin is not routine therapy for most RSV infections. Supportive care remains the main approach. Ribavirin is generally reserved for severe or life-threatening disease, particularly in patients with risk factors such as prematurity, chronic lung disease, congenital heart disease, or immunocompromise.

Mechanism of Action

Ribavirin is described as virostatic, meaning it inhibits viral replication rather than directly killing the virus. It resembles a natural nucleoside and interferes with the production of viable viral particles. Since it does not prevent viral attachment or entry into host cells, it reduces the severity of infection rather than completely preventing infection.

Delivery by SPAG

Ribavirin requires specialized delivery using a small-particle aerosol generator, or SPAG. This device produces a continuous aerosol. Ribavirin may be delivered by mask, hood, tent, or ventilator circuit.

A common preparation is 6 g of powder in 300 mL of sterile water, producing a 20 mg/mL solution. Therapy may be administered for prolonged periods, such as 12 to 18 hours per day for 3 to 7 days, depending on the protocol and patient situation. This makes ribavirin very different from many routine aerosol treatments that last only several minutes.

Respiratory and Systemic Effects

Ribavirin can be associated with several adverse effects. Pulmonary effects may include worsening lung function, bronchospasm, apnea, pneumothorax, bacterial pneumonia, and worsening asthma or COPD. Other reported concerns include cardiovascular instability, hypotension, cardiac arrest, digitalis toxicity, rash, eyelid redness, conjunctivitis, and skin irritation from aerosol residue.

Because of these risks, the patient should be monitored closely for changes in:

• Respiratory rate
• Work of breathing
• Oxygen requirement
• Breath sounds
• Wheezing
• Arterial blood gases
• Temperature
• Overall clinical appearance
• Signs of deterioration or improvement

Mechanical Ventilation Concerns

Ribavirin therapy is especially complex during mechanical ventilation. The drug can precipitate in the ventilator circuit and interfere with expiratory valves, sensors, and other components. Accumulated residue may increase expiratory resistance or contribute to endotracheal tube obstruction.

To reduce risk during mechanical ventilation, the setup may include:

• A one-way valve between the SPAG and ventilator circuit
• A filter before the ventilator exhalation valve
• Frequent filter changes
• Close monitoring of expiratory resistance
• Careful assessment of ventilator alarms
• Monitoring for endotracheal tube obstruction

Note: Ventilator function must be observed throughout therapy. Any unexpected increase in airway pressure, change in delivered volume, altered exhalation, or alarm pattern should be investigated immediately.

Health Care Worker Exposure

Ribavirin aerosol can expose caregivers to medication. Because treatments may last many hours, environmental contamination can become significant. Appropriate containment strategies, room ventilation, scavenging, filtration, and personal protective equipment are important.

Zanamivir

Zanamivir is an inhaled antiviral medication used for influenza. It is commonly known by the brand name Relenza. Unlike nebulized anti-infective agents, zanamivir is delivered as a dry powder by oral inhalation.

Indications

Zanamivir may be used for treatment of uncomplicated acute influenza in adults and children when symptoms have been present for no more than a short period, commonly no more than two days. It may also be used for prophylaxis in selected patients.

Vaccination remains the primary strategy for influenza prevention, especially in high-risk patients. Zanamivir is not a substitute for appropriate vaccination.

Mechanism of Action

Zanamivir is a neuraminidase inhibitor. Influenza viruses use surface proteins, including hemagglutinin and neuraminidase, to infect cells and spread. Neuraminidase helps newly formed viral particles leave infected cells and continue infection. By inhibiting neuraminidase, zanamivir interferes with viral release and limits progression of infection.

Dry Powder Inhaler Technique

Zanamivir requires adequate inspiratory flow. This is a major clinical concern. Patients who are very young, weak, severely dyspneic, or unable to follow instructions may not receive the intended dose.

Proper technique includes:

• Loading the dose correctly
• Exhaling away from the device
• Sealing the lips around the mouthpiece
• Inhaling deeply and forcefully
• Holding the breath briefly if able
• Monitoring for cough, wheezing, or breathing difficulty

Note: Dry powder inhalers are portable and convenient, but they depend on patient effort. They are not ideal for every patient or every clinical condition.

Adverse Effects

The main concern with zanamivir is bronchospasm. Patients with asthma, COPD, or uncontrolled reactive airway disease may be at increased risk for serious respiratory deterioration. If severe coughing, wheezing, or shortness of breath occurs shortly after inhalation, treatment should be stopped and the physician should be contacted.

Monitoring should include respiratory symptoms, breath sounds, wheezing, breathing pattern, and overall tolerance.

Treatment Sequence in Cystic Fibrosis

Many patients with cystic fibrosis receive multiple inhaled therapies. The order of therapy matters because mucus, airway narrowing, and inflammation can affect drug delivery.

A common sequence is:

• Bronchodilator first
• Mucolytic or secretion-mobilizing therapy next
• Airway clearance therapy after secretions are mobilized
• Inhaled corticosteroid if prescribed
• Inhaled antibiotic last

This sequence makes clinical sense. A bronchodilator helps open the airways and may reduce bronchospasm. Mucolytics or hypertonic saline may help thin or mobilize secretions. Airway clearance helps remove mucus from the bronchial tree. Steroids may reduce inflammation when indicated. The antibiotic is given last so that it can remain in the airways after secretions have been cleared.

For example, a patient with cystic fibrosis may receive a bronchodilator, followed by dornase alfa or hypertonic saline, followed by airway clearance with directed coughing. If Pseudomonas infection is present, the inhaled antibiotic may then be administered.

Note: This approach improves the likelihood that the antibiotic reaches the lower airways rather than being trapped in thick secretions.

Aerosol Delivery Devices

Device selection is essential in inhaled anti-infective therapy. The drug formulation often determines the delivery system. Using the wrong device may reduce drug delivery, increase treatment time, or create safety problems.

Small-Volume Nebulizers

Small-volume nebulizers are commonly used for liquid medications. They require less patient coordination than inhalers and can deliver larger doses. However, they have several disadvantages.

Potential disadvantages include:

• Longer treatment time
• Need for medication preparation
• Residual medication left in the cup
• Need for a gas source with some devices
• Risk of contamination if not cleaned properly
• Fugitive aerosol released into the room
• Environmental exposure to medications

Note: Small-volume nebulizers may be used for some formulations of tobramycin, pentamidine, and colistin. Pentamidine requires special attention to filtration and environmental control.

Electronic Vibrating Mesh Nebulizers

Electronic vibrating mesh nebulizers can produce fine particles with low residual volume and shorter treatment times. They are used for certain medications, including inhaled aztreonam with its specified system.

Advantages may include efficient delivery and less medication waste. Disadvantages include higher cost, need for training, mechanical failure risk, cleaning requirements, and device-specific maintenance.

Dry Powder Inhalers

Dry powder inhalers are portable and convenient but depend on inspiratory effort. They require the patient to inhale deeply and forcefully enough to disperse the powder. This can be a problem for young children, severely dyspneic patients, weak patients, or those with poor coordination.

Zanamivir is delivered as a dry powder inhaler. Tobramycin may also be available in a dry powder format depending on the product. Patients must be carefully instructed and assessed to ensure proper use.

Airway Irritation and Bronchospasm

A major concern with inhaled anti-infective agents is local airway irritation. Inhaled antibiotics and antivirals can cause cough, wheezing, bronchospasm, chest tightness, and decreased flow rates. This may be related to the medication itself, solution characteristics, dose, delivery system, or underlying airway reactivity.

Patients with asthma, COPD, cystic fibrosis, or reactive airways may be at greater risk. Bronchodilator pretreatment may be needed with certain medications, especially inhaled aztreonam and sometimes pentamidine or other irritating aerosols.

Before therapy, the clinician should assess:

• Baseline breath sounds
• Respiratory rate and pattern
• Work of breathing
• Oxygen saturation
• Cough
• Sputum production
• History of bronchospasm
• Peak flow or spirometry when appropriate

Note: After therapy, the clinician should reassess for signs of deterioration or improvement. A decrease in peak flow, new wheezing, increased dyspnea, or reduced FEV₁ may suggest bronchospasm or intolerance.

Infection Control and Environmental Safety

Aerosolized anti-infective therapy creates infection-control and occupational exposure concerns. Medication can escape from the nebulizer or be exhaled by the patient. These fugitive emissions may be inhaled by caregivers, family members, or other patients.

Pentamidine and ribavirin are specifically associated with health risks to health care providers. Aerosolized antibiotics also require caution because environmental contamination may contribute to antimicrobial exposure and possibly resistant organisms.

Strategies to reduce exposure may include:

• One-way valves
• Expiratory filters
• Filtered nebulizer systems
• Scavenging systems
• Negative-pressure rooms
• Treatment booths or stations
• HEPA filtration
• Appropriate personal protective equipment
• Proper room ventilation
• Avoiding unnecessary aerosolization

Note: Equipment must be selected and assembled correctly. Filters should be changed as directed. Nebulizers should be cleaned or discarded according to policy. In mechanically ventilated patients, filters and valves must be monitored to prevent increased resistance or equipment malfunction.

Cleaning and Disinfection of Equipment

Many patients receiving inhaled antibiotics use reusable nebulizers at home. This creates a risk of contamination if equipment is not cleaned and disinfected properly. Contaminated nebulizer equipment can introduce pathogens into the airway, which is especially dangerous for patients with cystic fibrosis or impaired immunity.

Patients and caregivers should be taught a consistent cleaning routine. General steps may include:

• Taking the nebulizer apart after use
• Washing parts with dish detergent and water
• Rinsing as directed
• Disinfecting by an approved heat or cold method
• Rinsing with sterile or filtered water when appropriate
• Allowing parts to air-dry completely
• Storing equipment in a clean location

Heat methods may include boiling, microwaving submerged parts, using a dishwasher at adequate temperature, or using an electric steam sterilizer. Cold methods may include soaking in 70% isopropyl alcohol or 3% hydrogen peroxide, depending on the device instructions and institutional guidance.

Note: Patients should follow manufacturer instructions because not all device parts tolerate the same cleaning methods.

Assessment Before Therapy

The respiratory therapist plays a central role in safe administration. Before treatment, the therapist should confirm the indication, review the medication order, assess the patient’s respiratory status, and identify risk factors.

Important pre-treatment checks include:

• Correct patient
• Correct medication
• Correct dose
• Correct device
• Correct frequency
• Correct indication
• Known allergies
• Baseline respiratory status
• Breath sounds
• Oxygen requirement
• Work of breathing
• Sputum characteristics
• Recent pulmonary function results
• Need for bronchodilator pretreatment
• Infection-control precautions
• Equipment setup and filtration

Note: For antibiotics, the therapist should understand whether the organism is suspected or confirmed. For cystic fibrosis patients, Pseudomonas aeruginosa status is especially important. For ribavirin, the severity of RSV disease and patient risk factors should be reviewed. For pentamidine, the prophylactic purpose should be clear.

Monitoring During Therapy

During therapy, the patient should be watched for tolerance and adverse effects. Inhaled anti-infectives can cause sudden respiratory symptoms, especially in patients with reactive airways.

The therapist should monitor:

• Respiratory rate
• Breathing pattern
• Pulse
• Oxygen saturation
• Breath sounds
• Cough
• Wheezing
• Chest tightness
• Work of breathing
• Patient appearance
• Anxiety or distress
• Ventilator function if mechanically ventilated
• Device performance
• Leaks or fugitive aerosol
• Filter resistance or obstruction

Note: If bronchospasm occurs, the treatment may need to be stopped. Bronchodilator therapy may be required. Severe allergic reaction, worsening respiratory distress, or equipment malfunction should be reported immediately.

Assessment After Therapy

After the treatment, the therapist should reassess the patient and document the response. Improvement may include better breath sounds, reduced work of breathing, improved oxygenation, improved secretion clearance, or improved patient comfort. However, some clinical benefits occur over days or weeks rather than immediately after one treatment.

Post-treatment assessment may include:

• Breath sounds
• Respiratory rate and effort
• Oxygen saturation
• Cough and sputum response
• Peak flow or spirometry when appropriate
• Side effects
• Patient tolerance
• Equipment cleaning or disposal
• Patient education provided

Note: For long-term inhaled antibiotic therapy, effectiveness may be measured by FEV₁ trends, exacerbation frequency, hospitalization rates, need for intravenous antibiotics, weight trends, and overall symptom burden.

Patient Education

Patient education is essential because many inhaled anti-infectives are used outside the hospital. Patients and caregivers must understand the purpose of the medication, how to use the device, how to clean equipment, what side effects to report, and how therapy fits into the overall treatment plan.

Important teaching points include:

• Why the medication was prescribed
• Which organism or infection it targets
• How often to take it
• Whether it is used in cycles
• What device to use
• Not to mix medications unless instructed
• When to use bronchodilator pretreatment
• Correct sequence with other inhaled therapies
• How to clean and disinfect equipment
• How to recognize bronchospasm or allergic reaction
• When to contact the health care provider
• Why adherence matters

Note: For dry powder inhalers, technique must be demonstrated and observed. For nebulizers, assembly, medication loading, treatment position, breathing technique, and cleaning must be reviewed.

Common Mistakes to Avoid

Several errors can reduce the effectiveness or safety of inhaled anti-infective therapy.

Common mistakes include:

• Using inhaled antibiotics for the wrong organism
• Treating cystic fibrosis patients with antibiotics without confirming Pseudomonas when required
• Giving the antibiotic before airway clearance
• Mixing tobramycin with other medications in the nebulizer
• Using the wrong nebulizer system for aztreonam
• Failing to pretreat with a bronchodilator when bronchospasm risk is high
• Ignoring cough, wheezing, or decreased FEV₁ after treatment
• Failing to use filters or containment precautions for pentamidine
• Not monitoring ventilator function during ribavirin therapy
• Allowing nebulizer equipment to remain wet or contaminated
• Assuming dry powder inhalers work well in patients with poor inspiratory effort
• Continuing therapy despite signs of severe hypersensitivity

Note: Avoiding these mistakes requires careful assessment, correct device use, and ongoing patient education.

Drug-by-Drug Summary

Tobramycin

Tobramycin is an inhaled aminoglycoside antibiotic used mainly for Pseudomonas aeruginosa infection in cystic fibrosis. It is often given in cycles and should not be mixed with other medications. Monitoring includes lung function, hearing-related symptoms, renal concerns, voice changes, cough, and bronchospasm.

Aztreonam

Aztreonam is an inhaled monobactam antibiotic used for Pseudomonas aeruginosa infection in cystic fibrosis. It requires a specific nebulizer system and is typically given after bronchodilator therapy, mucolytic therapy, and airway clearance. Major concerns include bronchospasm, decreased FEV₁, and allergic reaction.

Colistin

Colistin, or colistimethate sodium, is used against sensitive gram-negative organisms, including Pseudomonas aeruginosa. It may be used in cystic fibrosis and refractory gram-negative respiratory infections. Monitoring should include bronchospasm, airway irritation, kidney function, and neurologic symptoms.

Pentamidine

Pentamidine is an inhaled antiprotozoal agent used mainly for prophylaxis against Pneumocystis pneumonia in selected high-risk patients. It is not the preferred main treatment for active disease. Bronchospasm, cough, systemic side effects, and caregiver exposure are important concerns.

Ribavirin

Ribavirin is an inhaled antiviral used selectively for severe RSV lower respiratory tract infection, especially in high-risk patients. It requires a SPAG device and prolonged administration. During mechanical ventilation, drug precipitation can obstruct filters, valves, sensors, or airway tubing, so close monitoring is required.

Zanamivir

Zanamivir is an inhaled antiviral delivered by dry powder inhaler for influenza. It requires adequate inspiratory flow and correct technique. Bronchospasm is a major concern, especially in patients with asthma, COPD, or unstable airway disease.

Role of the Respiratory Therapist

The respiratory therapist is directly involved in safe and effective inhaled anti-infective therapy. The therapist must understand the medication, device, indication, patient risks, and environmental precautions.

Responsibilities include:

• Verifying the order and indication
• Selecting or confirming the correct delivery device
• Assessing baseline respiratory status
• Determining whether bronchodilator pretreatment is needed
• Setting up filters, valves, or containment systems when needed
• Monitoring patient response during treatment
• Watching for bronchospasm or allergic reaction
• Monitoring ventilator function during specialized aerosol therapy
• Teaching correct technique
• Reinforcing treatment sequence
• Educating about cleaning and disinfection
• Documenting response and adverse effects

Note: Because these medications are specific and sometimes complex, the therapist’s attention to detail can directly affect safety, drug delivery, and treatment success.

Inhaled Anti-Infective Agents Practice Questions

1. What are inhaled anti-infective agents?
Medications delivered directly into the respiratory tract to help prevent, treat, or manage selected infections of the lungs and airways.

2. Why is the inhaled route useful for some anti-infective medications?
It places the medication close to the site of infection while potentially limiting some systemic exposure.

3. Are inhaled anti-infective agents used for every respiratory infection?
No. They are reserved for specific organisms, diseases, patient groups, and clinical situations.

4. What are the main inhaled anti-infective agents discussed in respiratory care?
Pentamidine, ribavirin, inhaled tobramycin, inhaled aztreonam, colistimethate sodium, and zanamivir.

5. Which inhaled anti-infective agents are most associated with cystic fibrosis and Pseudomonas aeruginosa?
Tobramycin, aztreonam, and colistin.

6. What organism is inhaled tobramycin mainly used to manage in cystic fibrosis?
Pseudomonas aeruginosa.

7. Why is Pseudomonas aeruginosa important in patients with cystic fibrosis?
It is associated with chronic airway infection, worsening lung function, repeated exacerbations, and increased need for antibiotic therapy.

8. What class of antibiotic is tobramycin?
Tobramycin is an aminoglycoside antibiotic.

9. What is a major advantage of inhaled tobramycin in cystic fibrosis?
It can deliver high antibiotic concentrations directly to the airways while limiting systemic levels compared with intravenous therapy.

10. What are important adverse effects associated with inhaled tobramycin?
Voice alteration, tinnitus, cough, bronchospasm, airway irritation, and possible hearing or renal concerns.

11. Why should tobramycin be used cautiously in patients with renal problems?
Aminoglycosides can be associated with kidney toxicity, so renal function must be considered.

12. Why should tobramycin be used cautiously in patients with auditory or vestibular problems?
Aminoglycosides can be associated with hearing and balance-related toxicity.

13. Should TOBI be mixed with other medications in the nebulizer?
No. TOBI should be administered by itself and should not be mixed with other medications.

14. Why should tobramycin not be mixed with beta-lactam antibiotics?
It is incompatible with beta-lactam antibiotics such as penicillins and cephalosporins.

15. What monitoring is important during long-term inhaled tobramycin therapy?
FEV1 trends, hospitalizations, need for IV antipseudomonal therapy, weight changes, tinnitus, voice changes, hearing concerns, and renal concerns.

16. What should patients do after inhaled antibiotic treatments to reduce local irritation?
They should rinse and expectorate after treatment.

17. What is inhaled aztreonam used for?
It is used for cystic fibrosis patients with Pseudomonas aeruginosa infection.

18. What is the brand name commonly associated with inhaled aztreonam?
Cayston

19. What class of antibiotic is aztreonam?
Aztreonam is a monobactam antibiotic.

20. Why should inhaled aztreonam be administered by itself?
It is intended to be given alone through its specific delivery system and should not be mixed with other medications.

21. What device type is associated with inhaled aztreonam delivery?
A specific electronic vibrating mesh nebulizer system, such as the Altera system.

22. Why is bronchodilator pretreatment recommended before inhaled aztreonam?
Because aztreonam can cause bronchospasm and decreased FEV1.

23. What baseline assessment is important before starting inhaled aztreonam?
Baseline pulmonary function should be assessed.

24. Why should inhaled aztreonam not be used in cystic fibrosis patients without Pseudomonas infection?
Unnecessary antibiotic exposure can contribute to drug-resistant bacteria.

25. What adverse reaction should clinicians watch for when starting inhaled aztreonam?
They should watch for bronchospasm, decreased FEV1, and signs of allergic reaction.

26. What is colistimethate sodium also called?
Colistimethate sodium is also called colistin or polymyxin E.

27. What type of organisms is colistin used against?
Colistin is used against sensitive gram-negative bacilli, especially Pseudomonas aeruginosa.

28. Why is colistin relevant in cystic fibrosis care?
It may be used for Pseudomonas aeruginosa infection, which is a major chronic problem in cystic fibrosis.

29. What are important adverse effects associated with systemic colistimethate?
Neurotoxicity and nephrotoxicity are important adverse effects.

30. Why is monitoring still important when colistin is delivered by inhalation?
Because toxicity and airway irritation may still occur, even though the drug is delivered locally.

31. What is pentamidine isethionate?
Pentamidine isethionate is an antiprotozoal medication used mainly for Pneumocystis pneumonia prophylaxis.

32. What infection is pentamidine associated with?
Pentamidine is associated with Pneumocystis jirovecii pneumonia, also known as PJP.

33. In what patient population is Pneumocystis jirovecii pneumonia most common?
It is most common in immunocompromised patients, especially those with impaired immune function.

34. What medication is preferred for Pneumocystis pneumonia prophylaxis when tolerated?
Oral trimethoprim/sulfamethoxazole is preferred when it can be tolerated.

35. When may aerosolized pentamidine be used?
It may be used as an alternative for primary or secondary prophylaxis when the preferred medication is not appropriate.

36. Is aerosolized pentamidine recommended as the main treatment for active PJP?
No. Its role is mainly preventive, not the primary treatment for active PJP.

37. What respiratory adverse effects can occur with inhaled pentamidine?
Cough, bronchial irritation, wheezing, bronchospasm, shortness of breath, and chest pain may occur.

38. What taste-related side effect may occur with aerosolized pentamidine?
A bad or metallic taste may occur.

39. What systemic effects have been reported with pentamidine?
Nausea, dizziness, chills, night sweats, renal insufficiency, hypoglycemia, neutropenia, pancreatitis, and fatigue have been reported.

40. Why should patients be monitored closely during pentamidine administration?
Because bronchospasm and airway irritation can occur, especially in patients with reactive airways.

41. What concern exists with prophylactic inhaled pentamidine outside the lungs?
It may not fully prevent extrapulmonary Pneumocystis infection.

42. What environmental safety concern is associated with aerosolized pentamidine?
Escaped aerosol may expose caregivers or bystanders to the medication.

43. What type of nebulizer setup is recommended for pentamidine?
A nebulizer with one-way valves and a downstream particle filter is recommended.

44. Why are one-way valves and filters useful during pentamidine therapy?
They help trap exhaled aerosol droplets and reduce contamination of the surrounding environment.

45. What is ribavirin?
Ribavirin is an inhaled antiviral agent used selectively for severe RSV infection.

46. What does RSV stand for?
RSV stands for respiratory syncytial virus.

47. Is ribavirin routine therapy for most RSV infections?
No. Ribavirin is generally reserved for severe or life-threatening RSV disease.

48. Which patients are more likely to be considered for ribavirin therapy?
High-risk patients such as premature infants, those with chronic lung disease, congenital heart disease, or immunocompromise.

49. What remains the foundation of RSV management?
Supportive care remains the foundation of RSV management.

50. How should ribavirin be viewed in RSV treatment?
It should be viewed as a selective therapy rather than a standard treatment for every RSV infection.

51. What device is used to deliver inhaled ribavirin?
Ribavirin is delivered with a small-particle aerosol generator, often called SPAG.

52. What does SPAG stand for?
SPAG stands for small-particle aerosol generator.

53. What types of interfaces can be used to deliver ribavirin?
Ribavirin can be delivered by mask, hood, tent, or ventilator circuit.

54. Why is ribavirin therapy considered complex?
It can expose caregivers to aerosolized medication and may precipitate in ventilator circuits.

55. What problem can ribavirin precipitation cause during mechanical ventilation?
It can obstruct the circuit, interfere with exhalation valves, or increase expiratory resistance.

56. What can be placed before the ventilator exhalation valve during ribavirin therapy?
A filter can be placed before the ventilator exhalation valve.

57. Why must filters be changed frequently during ribavirin therapy?
They must be changed frequently to prevent increased expiratory resistance from drug accumulation.

58. What should be monitored closely when ribavirin is delivered during mechanical ventilation?
Ventilator function, exhalation valves, filters, airway patency, alarms, and signs of increased resistance should be monitored.

59. What type of drug action is ribavirin described as having?
Ribavirin is virostatic, meaning it inhibits viral replication.

60. Does ribavirin prevent viral attachment or penetration into host cells?
No. It does not prevent viral attachment or penetration into host cells.

61. What are possible pulmonary adverse effects of ribavirin?
Bronchospasm, worsening lung function, apnea, pneumothorax, bacterial pneumonia, and worsening asthma or COPD may occur.

62. What skin or eye effects may occur from ribavirin aerosol exposure?
Skin irritation, rash, eyelid redness, and conjunctivitis may occur.

63. What cardiovascular problems have been reported with ribavirin?
Cardiovascular instability, hypotension, cardiac arrest, and digitalis toxicity have been reported.

64. What infection is zanamivir used for?
Zanamivir is used for influenza.

65. What is the common brand name for zanamivir?
Relenza

66. What type of inhaler is used to deliver zanamivir?
Zanamivir is delivered by dry powder inhaler.

67. Why does zanamivir require adequate inspiratory effort?
The patient must inhale forcefully enough to disperse and deliver the dry powder into the airways.

68. Which patients may have difficulty using zanamivir effectively?
Very young, weak, severely dyspneic, or poorly coordinated patients may have difficulty generating adequate inspiratory flow.

69. What is the proper technique for using zanamivir?
The patient should load the dose, exhale away from the device, seal the lips around the mouthpiece, inhale deeply and forcefully, and then be monitored for response.

70. What drug class does zanamivir belong to?
Zanamivir is a neuraminidase inhibitor.

71. How does zanamivir limit influenza infection?
It blocks neuraminidase, which interferes with viral release from infected cells.

72. Why is zanamivir not a substitute for influenza vaccination?
Vaccination remains the primary prevention strategy, especially for high-risk patients.

73. What is the main respiratory safety concern with zanamivir?
Bronchospasm is the main respiratory safety concern.

74. Which patients are at higher risk for serious respiratory problems with zanamivir?
Patients with asthma, COPD, or unstable reactive airway disease are at higher risk.

75. What should be done if severe coughing or wheezing occurs after zanamivir?
Treatment should be stopped, and the physician should be contacted.

76. What is meant by fugitive emissions during aerosol therapy?
Fugitive emissions are aerosol particles that escape from the nebulizer or are exhaled by the patient into the surrounding air.

77. Why are fugitive emissions important during inhaled anti-infective therapy?
They may expose caregivers, bystanders, or other patients to aerosolized medications or contaminated respiratory particles.

78. Which inhaled anti-infective agents are especially associated with health risks to caregivers?
Pentamidine and ribavirin are especially associated with caregiver exposure concerns.

79. Why should aerosolized antibiotics be handled carefully in health care settings?
Environmental exposure to antibiotics may contribute to contamination and possibly promote resistant organisms.

80. What environmental control methods may be used during inhaled anti-infective therapy?
One-way valves, expiratory filters, scavenging systems, negative-pressure rooms, HEPA filtration, booths, stations, and personal protective equipment may be used.

81. What should the respiratory therapist verify before administering an inhaled anti-infective agent?
The therapist should verify the indication, medication, dose, delivery device, patient risk factors, contraindications, and need for bronchodilator pretreatment.

82. What baseline respiratory findings should be assessed before treatment?
Respiratory rate, breathing pattern, pulse, breath sounds, work of breathing, oxygenation, cough, and sputum production should be assessed.

83. Why may peak flow be checked before and after inhaled antibiotic therapy?
Peak flow can help identify airway narrowing or bronchospasm caused by the treatment.

84. Why may chest auscultation be performed before and after therapy?
It helps detect changes in breath sounds, wheezing, secretion movement, or signs of airway irritation.

85. What symptoms should be monitored during inhaled anti-infective therapy?
Chest tightness, worsening shortness of breath, cough, wheezing, throat irritation, and signs of allergic reaction should be monitored.

86. What should the therapist do after administering an inhaled anti-infective agent?
The therapist should reassess the patient, document the response, note adverse effects, reinforce education, and ensure equipment is cleaned or discarded properly.

87. Why is treatment sequencing important in cystic fibrosis patients receiving inhaled antibiotics?
Proper sequencing helps clear mucus and open the airways before the antibiotic is delivered, improving the chance of lower airway deposition.

88. What is the recommended sequence when multiple inhaled therapies are prescribed for cystic fibrosis?
Bronchodilator, mucolytic, airway clearance therapy, inhaled corticosteroid if ordered, and aerosolized antibiotic last.

89. What does the phrase “open, thin, clear, calm, kill” mean?
It means open the airways with a bronchodilator, thin secretions, clear mucus, calm inflammation if ordered, and give the antibiotic last.

90. Why are inhaled antibiotics usually given after airway clearance therapy?
They are given after airway clearance so the medication can reach the airways more effectively instead of being trapped in retained secretions.

91. What pulmonary function measurement is especially important in cystic fibrosis monitoring?
FEV1 is especially important because declining FEV1 reflects worsening airflow obstruction and disease progression.

92. What sputum changes may help assess response to therapy?
Changes in sputum amount, color, thickness, and ease of expectoration may help assess infection status and treatment response.

93. Why must reusable nebulizer equipment be cleaned and disinfected properly?
Contaminated nebulizer equipment can introduce microorganisms into the airway and increase infection risk.

94. What are general steps for cleaning reusable nebulizer equipment?
Disassemble the device, wash parts with detergent and water, disinfect using an approved method, rinse as directed, air-dry, and store in a clean place.

95. What are examples of heat disinfection methods for nebulizer equipment?
Boiling, microwaving submerged parts, using a dishwasher at adequate temperature, or using an electric steam sterilizer may be used when allowed by the manufacturer.

96. What are examples of cold disinfection methods for nebulizer equipment?
Soaking parts in 70% isopropyl alcohol or 3% hydrogen peroxide may be used when appropriate for the device.

97. Why should dry powder inhalers not be used without assessing patient ability?
They require adequate inspiratory flow and technique, so some patients may not receive the intended dose.

98. What should be done if an inhaled anti-infective causes significant bronchospasm?
The treatment should be stopped or reassessed, bronchodilator therapy may be needed, and the health care provider should be notified.

99. What is the most important way to remember the major inhaled anti-infective agents?
Pair each drug with its target: tobramycin, aztreonam, and colistin for Pseudomonas in cystic fibrosis; pentamidine for Pneumocystis prophylaxis; ribavirin for RSV; and zanamivir for influenza.

100. What factors determine safe and effective inhaled anti-infective therapy?
Correct patient selection, confirmed or suspected organism, proper device use, treatment sequencing, close monitoring, infection control, and equipment cleaning determine safe and effective therapy.

Final Thoughts

Inhaled anti-infective agents are specialized medications used for selected respiratory infections and high-risk clinical situations. Their value depends on matching the drug to the correct organism, patient, delivery device, and treatment goal.

Tobramycin, aztreonam, and colistin are strongly associated with Pseudomonas infection in cystic fibrosis. Pentamidine is used for Pneumocystis prophylaxis, ribavirin for severe RSV disease, and zanamivir for influenza.

These therapies require careful monitoring because bronchospasm, toxicity, allergic reactions, device problems, and environmental exposure can occur. Safe use depends on accurate assessment, proper sequencing, correct equipment, infection control, and clear patient education.